Economic value of pre-travel health interventions for communicable diseases in international travellers.
Uložené v:
| Názov: | Economic value of pre-travel health interventions for communicable diseases in international travellers. |
|---|---|
| Autori: | Stanic T; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA., Koiso S; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA., Fields NF; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA., Walker AT; Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, USA., Mulroy NM; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA., Ryan ET; Traveler's Advice and Immunization Center, Massachusetts General Hospital, Boston, MA, USA.; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., LaRocque RC; Traveler's Advice and Immunization Center, Massachusetts General Hospital, Boston, MA, USA.; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hyle EP; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA.; Traveler's Advice and Immunization Center, Massachusetts General Hospital, Boston, MA, USA.; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA. |
| Zdroj: | Journal of travel medicine [J Travel Med] 2025 Nov 23; Vol. 32 (7). |
| Spôsob vydávania: | Journal Article; Review |
| Jazyk: | English |
| Informácie o časopise: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9434456 Publication Model: Print Cited Medium: Internet ISSN: 1708-8305 (Electronic) Linking ISSN: 11951982 NLM ISO Abbreviation: J Travel Med Subsets: MEDLINE |
| Imprint Name(s): | Publication: Jan. 2016- : Oxford : Oxford University Press, Original Publication: Hamilton, ON, Canada : Decker Periodicals, c1994. |
| Výrazy zo slovníka MeSH: | Travel*/economics , Communicable Disease Control*/economics , Communicable Disease Control*/methods , Communicable Diseases*/economics, Humans ; Cost-Benefit Analysis ; Vaccination/economics |
| Abstrakt: | Background: Pre-travel health interventions can reduce the acquisition of communicable diseases and decrease the risk of transmission during or after international travel. We sought to inform policy and research priorities with a scoping literature review of studies that assess the cost-effectiveness of pre-travel interventions. Methods: We assessed 44 economic evaluation studies published from 1946-2023, regarding pre-travel prevention of hepatitis A, hepatitis B, influenza, malaria, rabies, travellers' diarrhoea, cholera, polio, typhoid fever, measles, and Japanese encephalitis. Results: Published studies demonstrate that hepatitis A vaccination, malaria chemoprophylaxis and typhoid vaccination for people travelling to highly endemic settings are likely to be cost-effective, as is measles-mumps-rubella vaccination. The cost-effectiveness of other pre-travel interventions is more sensitive to travel frequency and duration, endemicity at the travel destination, travel purpose (e.g. business, leisure, visiting friends and relatives), risk perceptions (e.g. adherence to care plan, choosing to vaccinate), and costs. Conclusions: Cost-effectiveness analyses of pre-travel interventions can inform the value of such interventions, but such analyses depend on the availability of high-quality data regarding clinical outcomes and costs. We propose that international, collaborative networks should collect data and leverage novel technologies to expand the evidence base regarding the risks of exposure, clinical outcomes, risk perception, and costs associated with pre-travel interventions. This evidence base can inform recommendations for specific groups of travellers and the formulation of population-specific health policies. (© The Author(s) 2025. Published by Oxford University Press on behalf of the International Society of Travel Medicine.) |
| References: | J Travel Med. 2023 Feb 18;30(1):. (PMID: 35904457) J Med Virol. 1994 Dec;44(4):463-9. (PMID: 7897383) Arch Intern Med. 1994 Mar 28;154(6):663-8. (PMID: 8129500) J Travel Med. 2009 Jan-Feb;16(1):28-34. (PMID: 19192125) CMAJ. 1992 Jun 1;146(11):1947-52. (PMID: 1596843) Malar J. 2011 May 17;10:130. (PMID: 21586155) BMC Infect Dis. 2009 May 16;9:65. (PMID: 19445712) BMJ. 1994 Oct 8;309(6959):918-22. (PMID: 7726905) Clin Infect Dis. 2006 Dec 15;43(12):1499-539. (PMID: 17109284) BMC Infect Dis. 2010 Sep 22;10:279. (PMID: 20860809) Clin Microbiol Infect. 2004 Aug;10(8):681-3. (PMID: 15301670) J Travel Med. 2022 Mar 21;29(2):. (PMID: 35085399) Vaccine. 2021 Jul 30;39(33):4733-4741. (PMID: 34030898) Pharmacoeconomics. 1996 Nov;10(5):475-83. (PMID: 10163629) BMJ Open. 2024 Jul 27;14(7):e083065. (PMID: 39067885) Vaccine. 2014 Sep 8;32(40):5156-62. (PMID: 25086264) Clin Infect Dis. 2020 Sep 12;71(6):1568-1576. (PMID: 31967305) Epidemiol Infect. 2001 Oct;127(2):347-51. (PMID: 11693513) Vaccine. 2019 Mar 7;37(11):1467-1475. (PMID: 30770225) PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072) Pharmacoeconomics. 1997 Sep;12(3):361-73. (PMID: 10170461) Clin Infect Dis. 2012 Feb 15;54(4):455-62. (PMID: 22144534) Vaccine. 1992;10 Suppl 1:S88-92. (PMID: 1335668) MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):780. (PMID: 28749924) J Infect. 1998 Jan;36(1):17-22. (PMID: 9515663) Vaccine. 2017 Jul 5;35(31):3823-3833. (PMID: 28606811) Int J Technol Assess Health Care. 1994 Summer;10(3):490-7. (PMID: 8071009) MMWR Recomm Rep. 2024 Aug 29;73(5):1-25. (PMID: 39197095) Pediatrics. 2021 Apr;147(4):. (PMID: 33712549) Curr Opin Infect Dis. 2011 Oct;24(5):403-9. (PMID: 21788892) Vaccine. 1996 Feb;14(2):167-76. (PMID: 8852415) Vaccine. 2020 Apr 9;38(17):3351-3357. (PMID: 32169391) Health Policy Plan. 2017 May 01;32(4):538-548. (PMID: 28104695) Am J Trop Med Hyg. 2017 Dec;97(6):1857-1866. (PMID: 29016296) MMWR Morb Mortal Wkly Rep. 2023 Feb 24;72(8):210-211. (PMID: 36821716) Vaccine. 1991 Nov;9(11):833-6. (PMID: 1759505) J Travel Med. 2009 Sep-Oct;16(5):344-8. (PMID: 19796106) Int J Epidemiol. 1998 Feb;27(1):118-20. (PMID: 9563704) JAMA. 2016 Sep 13;316(10):1093-103. (PMID: 27623463) Trop Dis Travel Med Vaccines. 2018 Nov 7;4:14. (PMID: 30455974) Curr Opin Infect Dis. 2021 Oct 1;34(5):423-431. (PMID: 34267046) Arch Intern Med. 1988 Nov;148(11):2421-7. (PMID: 3142381) J Travel Med. 2024 Dec 10;31(8):. (PMID: 39167759) Clin Infect Dis. 2014 Jan;58(1):11-21. (PMID: 24014735) Health Policy. 2008 Dec;88(2-3):186-99. (PMID: 18440663) Euro Surveill. 2020 Sep;25(38):. (PMID: 32975187) Pharmacoeconomics. 1995 Jul;8(1):46-61. (PMID: 10155601) Br J Gen Pract. 1996 Sep;46(410):541-2. (PMID: 8917876) J Travel Med. 2023 Nov 18;30(7):. (PMID: 37341307) West J Med. 2000 Nov;173(5):325-9. (PMID: 11069868) J Travel Med. 2024 Dec 10;31(8):. (PMID: 38578987) Lancet Infect Dis. 2023 Feb;23(2):196-206. (PMID: 36216018) MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23. (PMID: 16708058) BMJ. 1999 May 15;318(7194):1349. (PMID: 10323827) Mil Med. 1998 Aug;163(8):564-7. (PMID: 9715622) J Travel Med. 2022 Jul 14;29(4):. (PMID: 35348741) MMWR Recomm Rep. 2019 Jul 19;68(2):1-33. (PMID: 31518342) Infect Dis Now. 2022 Sep;52(6):349-357. (PMID: 35760347) JAMA Pediatr. 2020 Feb 1;174(2):e194515. (PMID: 31816033) J Travel Med. 2024 Jul 7;31(5):. (PMID: 38813965) J Travel Med. 2023 Nov 18;30(7):. (PMID: 37602668) Vaccine. 2008 May 12;26(20):2490-502. (PMID: 18417259) MMWR Morb Mortal Wkly Rep. 2022 Nov 18;71(46):1465-1470. (PMID: 36395065) J Travel Med. 2020 Dec 23;27(8):. (PMID: 33247586) J Travel Med. 2002 Mar-Apr;9(2):71-5. (PMID: 12044273) Vaccine. 1994 Nov;12(15):1379-83. (PMID: 7887014) Public Health Rep. 2003 Nov-Dec;118(6):550-8. (PMID: 14563912) Crit Care Clin. 2012 Jan;28(1):11-24, v. (PMID: 22123096) Clin Infect Dis. 2019 Jul 2;69(2):306-315. (PMID: 30312374) Am J Public Health. 2010 Jul;100(7):1249-52. (PMID: 20466959) J Travel Med. 2018 Jan 1;25(1):. (PMID: 29788400) Vaccine. 2013 Aug 20;31(37):4024-32. (PMID: 23707166) PLoS One. 2020 Sep 23;15(9):e0239385. (PMID: 32966315) J Travel Med. 1994 Sep 1;1(3):127-135. (PMID: 9815326) J Travel Med. 2024 Jan 28;31(1):. (PMID: 37410376) J Occup Environ Med. 2019 Jan;61(1):16-20. (PMID: 30320627) J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):257-266. (PMID: 35333347) MMWR Morb Mortal Wkly Rep. 2022 May 06;71(18):619-627. (PMID: 35511716) Int Marit Health. 2002;53(1-4):36-42. (PMID: 12608587) J Travel Med. 2023 Jun 23;30(4):. (PMID: 37074157) |
| Grant Information: | U01 CK000175 United States CK NCEZID CDC HHS; U01 CK000633 United States CK NCEZID CDC HHS; U01CK000633 United States CC CDC HHS; U01CK000175 United States CC CDC HHS; Claflin Distinguished Scholars Award (EPH) |
| Contributed Indexing: | Keywords: Pre-travel health intervention; communicable diseases; cost-effectiveness |
| Entry Date(s): | Date Created: 20250629 Date Completed: 20251124 Latest Revision: 20251126 |
| Update Code: | 20251126 |
| PubMed Central ID: | PMC12640876 |
| DOI: | 10.1093/jtm/taaf053 |
| PMID: | 40581744 |
| Databáza: | MEDLINE |
Nájsť tento článok vo Web of Science | Abstrakt: | Background: Pre-travel health interventions can reduce the acquisition of communicable diseases and decrease the risk of transmission during or after international travel. We sought to inform policy and research priorities with a scoping literature review of studies that assess the cost-effectiveness of pre-travel interventions.<br />Methods: We assessed 44 economic evaluation studies published from 1946-2023, regarding pre-travel prevention of hepatitis A, hepatitis B, influenza, malaria, rabies, travellers' diarrhoea, cholera, polio, typhoid fever, measles, and Japanese encephalitis.<br />Results: Published studies demonstrate that hepatitis A vaccination, malaria chemoprophylaxis and typhoid vaccination for people travelling to highly endemic settings are likely to be cost-effective, as is measles-mumps-rubella vaccination. The cost-effectiveness of other pre-travel interventions is more sensitive to travel frequency and duration, endemicity at the travel destination, travel purpose (e.g. business, leisure, visiting friends and relatives), risk perceptions (e.g. adherence to care plan, choosing to vaccinate), and costs.<br />Conclusions: Cost-effectiveness analyses of pre-travel interventions can inform the value of such interventions, but such analyses depend on the availability of high-quality data regarding clinical outcomes and costs. We propose that international, collaborative networks should collect data and leverage novel technologies to expand the evidence base regarding the risks of exposure, clinical outcomes, risk perception, and costs associated with pre-travel interventions. This evidence base can inform recommendations for specific groups of travellers and the formulation of population-specific health policies.<br /> (© The Author(s) 2025. Published by Oxford University Press on behalf of the International Society of Travel Medicine.) |
|---|---|
| ISSN: | 1708-8305 |
| DOI: | 10.1093/jtm/taaf053 |